Rogaratinib - Bayer

Drug Profile

Rogaratinib - Bayer

Alternative Names: BAY-1163877

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 05 Apr 2018 Bayer plans a phase I trial for Healthy volunteers in the Netherlands , (NCT03484585)
  • 22 Mar 2018 Bayer plans a phase I/II study for Urogenital-cancer (Metastatic disease, Late-stage disease) in USA, Austria , France, Germany, Italy, Japan, Spain and South Korea (NCT03473756)
  • 25 Jan 2018 Bayer plans a phase II/III trial for FGFR-positive Urogenital-cancer (Late-stage disease, Second-line or greater therapy) in Austria, Canada, Czechia, Denmark, Finland, France, Hong Kong, Israel, Italy, South Korea, Portugal, Russia, Singapore, Slovakia, Spain, Switzerland, Taiwan , (NCT03410693)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top